摘要
目的:研究5-烯丙基-7-二氟亚甲基白杨素(ADFMChR)对人卵巢癌COC1裸鼠移植瘤生长的影响。方法:建立人卵巢癌COC1裸鼠皮下移植瘤模型,随机分为5组:生理盐水组、顺铂组(2mg/kg)、低剂量ADFMChR组(6mg/kg)、中剂量ADFMChR组(18mg/kg)和高剂量ADFMChR组(54mg/kg),每组4只。观察各组裸鼠移植瘤生长情况,裸鼠体重的变化,检测裸鼠血清谷丙转氨酶(ALT)、乳酸脱氢酶(LDH)、肌酐(CRE)及外周血白细胞计数;PI染色流式细胞术(FCM)测定移植瘤细胞凋亡率。结果:ADFM-ChR有明显抑制移植瘤生长的作用,低剂量组、中剂量组和高剂量组的瘤重抑制率分别为42.86%,62.76%和77.55%。ADFMChR3种剂量组处理裸鼠的外周血白细胞数和血清谷丙转氨酶(ALT)、乳酸脱氢酶(LDH)、肌酐(CRE)与生理盐水对照组的差异均无统计学意义(P>0.05)。PI流式细胞术结果显示ADFMChR诱导移植瘤细胞凋亡,呈剂量依赖性。结论:ADFMChR通过诱导细胞凋亡抑制人卵巢癌裸鼠移植瘤的生长。
Objective: To investigate the effect of 5-allyl-7-gen-difluoromethyleneehrysin (ADFMChR) on the growth of human ovarian carcinoma xenografts in nude mice. Methods:Model of human ovarian cancer transplanted subcutaneously in nude mice was established, and divided into 5 groups : control group, DDP (2mg/kg) group, low dose ADFMChR (6mg/kg) group,media close ADFMChR(18mg/kg) group and high dose ADFMChR(54mg/ kg) group. Tumor volume and weight were measured. The serum levels of AST,ALT,LDH and CRE as well as white blood cell counts were determined. The rate of apoptotic ceils of human ovarian carcinoma xenografts was analyzed by PI stained FCM. Results:ADFMChR could significantly suppress tumor growth of human ovarian carcinoma xenografts in mouse models. After treatment with ADFMChR (6,18 and 54mg/kg), the inhibitory rates of the weight of human ovarian carcinoma xenografts were 42.86% ,62.76% and 77.55% respectively. There was no obvious difference in the serum levels of ALT, LDH and CRE as well as WBCs between the mice treated with ADFMChR of different dose and those treated with normal saline. Analysis by FCM showed that the apoptotic percentages in human ovarian cancer xenografts induced by ADFMChR increased,in a dose-manner. Conclusion:ADFMChR suppresses the growth of human ovarian carcinoma xen
出处
《现代妇产科进展》
CSCD
北大核心
2009年第1期22-25,共4页
Progress in Obstetrics and Gynecology
基金
湖南省科技厅科研项目(No:06FJ3125)
关键词
卵巢肿瘤
5-烯丙基-7-二氟亚甲基白杨素
治疗应用
凋亡
use
Apoptosis ografts in nude mice through induction of apoptosis of xenograft cells Ovarian neoplasms
5-allyl-7-gen- difluoromethylenechrysin
Therapeutic